[Federal Register Volume 90, Number 173 (Wednesday, September 10, 2025)]
[Notices]
[Page 43615]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-17380]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Charter Amendments, Establishments, Reestablishments, Renewals, 
and Terminations; Novel and Exceptional Technology and Research 
Advisory Committee

    Pursuant to Title 41 of the U.S. Code of Federal Regulations, 
Section 102-3.65(a), the Director, National Institutes of Health (NIH) 
announces the re-establishment of the Novel and Exceptional Technology 
and Research Advisory Committee as authorized by 42 U.S.C. 282(b)(16), 
section 402(b)(16) of the Public Health Service Act, as amended.
    The Director, NIH, has determined that the current activities of 
the Novel and Exceptional Technology and Research Advisory Committee 
are in the public interest in connection with the performance of duties 
imposed on NIH by law, and that these duties can best be performed 
through the advice and counsel of the committee.
    This committee provides advice and recommendations on matters 
related to the conduct and oversight of research involving emerging 
technologies in biomedical science (also referred to as emerging 
biotechnologies).
    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Novel and 
Exceptional Technology and Research Advisory Committee.
    The meeting will be held as a virtual meeting and will be open to 
the public as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting should notify the Contact Person listed below in 
advance of the meeting. The meeting will be accessible through the 
following link (https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4/).

    Name of Committee: Novel and Exceptional Technology and Research 
Advisory Committee.
    Date: September 29, 2025.
    Time: 1:00 p.m.-3:00 p.m. ET.
    Agenda: The Novel and Exceptional Technology and Research 
Advisory Committee (NExTRAC) meeting will include presentation, 
discussion, and possible finalization of the Draft Report of the 
Working Group on Engaging the Public as Partners in Clinical 
Research.
    Place: National Institutes of Health, 6705 Rockledge Drive, 
Suite 630, Bethesda, MD 20892 (https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4/).
    Contact Person: Jessica Tucker, Ph.D., Office of Science Policy, 
National Institutes of Health, 6705 Rockledge Drive, Suite 630, 
Bethesda, MD 20892, 301-496-9838, [email protected].
    Any interested person may file written comments by forwarding 
the statement to the Contact Person listed on this notice at least 
two business days prior to the meeting date. The statement should 
include the name, address, telephone number and when applicable, the 
business or professional affiliation of the interested person. Other 
than name and contact information, please do not include any 
personally identifiable information or any information that you do 
not wish to make public. Proprietary, classified, confidential, or 
sensitive information should not be included in your comments. 
Please note that any comments NIH receives may be posted unredacted 
to the Office of Science Policy website.
    Information is also available on the NIH Office of Science 
Policy website: https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4, 
where an agenda, link to the webcast meeting, and any additional 
information for the meeting will be posted when available. Materials 
for this meeting will be posted prior to the meeting. Please check 
this website for updates.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: September 4, 2025.
Jayantha Bhattacharya,
Director, National Institutes of Health.
[FR Doc. 2025-17380 Filed 9-9-25; 8:45 am]
BILLING CODE 4140-01-P